Biohaven Pharmaceutical Stock Forecast, Price & News

+2.01 (+2.12 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume941,580 shs
Average Volume654,037 shs
Market Capitalization$6.31 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical logo

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.23 out of 5 stars

Medical Sector

936th out of 2,105 stocks

Pharmaceutical Preparations Industry

455th out of 832 stocks

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Biohaven Pharmaceutical?

Wall Street analysts have given Biohaven Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biohaven Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Biohaven Pharmaceutical

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) announced its earnings results on Sunday, May, 9th. The company reported ($4.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.92) by $1.29. The business earned $43.82 million during the quarter, compared to the consensus estimate of $36.46 million. The company's quarterly revenue was up 3710.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.39) earnings per share.
View Biohaven Pharmaceutical's earnings history

How has Biohaven Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BHVN shares have increased by 145.8% and is now trading at $97.00.
View which stocks have been most impacted by COVID-19

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $43.80 million-$43.80 million, compared to the consensus revenue estimate of $36.41 million.

What price target have analysts set for BHVN?

10 Wall Street analysts have issued 12-month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $69.00 to $140.00. On average, they anticipate Biohaven Pharmaceutical's share price to reach $103.89 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:
  • Dr. Vladimir Coric, CEO, Pres & Director (Age 50, Pay $1.26M)
  • Mr. James Engelhart, CFO & Treasurer (Age 57, Pay $717.04k)
  • Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 55, Pay $654.99k)
  • Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $726.79k)
  • Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 57, Pay $931.82k)
  • Mr. Matthew DeLawder, Director of Accounting
  • Dr. Charles Conway, Chief Scientific Officer (Age 59)
  • Ms. Wendy Goss, Exec. Admin. Assistant
  • Mr. Clifford Bechtold M.S., Pres & GM of Biohaven Ireland and Chief Compliance Officer
  • Ms. Jenny Strauss M.P.H., Mang. of Medical Information & Communication

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capital International Investors (8.57%), BlackRock Inc. (6.10%), Stifel Financial Corp (3.94%), JPMorgan Chase & Co. (2.83%), Alliancebernstein L.P. (2.35%) and Bank of New York Mellon Corp (1.91%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical

Which institutional investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Cormorant Asset Management LP, Nuveen Asset Management LLC, Morgan Stanley, Barclays PLC, Opaleye Management Inc., Panagora Asset Management Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Gregory Bailey, Kimberly Gentile, Robert Berman, and William A Jones Jr.
View insider buying and selling activity for Biohaven Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Biohaven Pharmaceutical stock?

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenview Capital Management LLC, Armistice Capital LLC, Bank of New York Mellon Corp, Oak Ridge Investments LLC, BlackRock Inc., Alliancebernstein L.P., and Capital International Investors. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric.
View insider buying and selling activity for Biohaven Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $97.00.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $6.31 billion and generates $63.63 million in revenue each year. The company earns $-766,800,000.00 in net income (profit) each year or ($13.06) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 825 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.

This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.